Navigation Links
Phase 3 Results for Alogliptin Demonstrated Significant Blood Sugar Reductions in Monotherapy and Four Add-on Therapy Studies
Date:6/7/2008

Data from five pivotal phase 3 studies presented at the American Diabetes

Association 68th Scientific Sessions

SAN FRANCISCO, June 7 /PRNewswire/ -- Results from five pivotal phase 3 studies of alogliptin were announced today at the American Diabetes Association (ADA) 68th Scientific Sessions by Takeda Global Research & Development Center, Inc. Alogliptin, which has been shown to be a highly selective inhibitor of dipeptidyl peptidase-4 (DPP-4), is currently under investigation as an oral treatment for type 2 diabetes. Alogliptin administered once daily demonstrated statistically significant reductions in hemoglobin A1c (HbA1c) versus placebo as a monotherapy and as an add-on therapy with the major classes of type 2 diabetes medications: metformin, thiazolidinediones, insulin and sulfonylureas.

"Almost half the patients with type 2 diabetes are not at the American Diabetes Association recommended HbA1c goal of less than 7 percent, so it's important to have new treatment options that are both effective and well tolerated to potentially address the large number of patients who aren't adequately controlled," said Richard Pratley, MD, director of the Diabetes & Metabolism Translational Medicine Unit at the University of Vermont College of Medicine. "These clinical data show that alogliptin effectively reduces blood sugar in patients, alone or when used in combination with existing oral anti-diabetic treatments as well as insulin, increasing the range of treatment options for patients."

In the alogliptin monotherapy study, a significantly greater percentage of patients achieved HbA1c levels of less than or equal to 7 percent. Similar results were seen in the add-on to metformin, thiazolidinedione and sulfonylurea studies. Across all studies, patients achieved significant reductions in HbA1c, up to 0.80 percent, depending on the alogliptin dose and their treatment regimen. Greater HbA1c reductions were seen in patients with h
'/>"/>

SOURCE Takeda Global Research & Development
Copyright©2008 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3 4

Related medicine technology :

1. New Diabetes Compound AVE0010 Showed Clear Dose Response Results With Once-A-Day Injection in Phase IIb Study
2. Synvista Therapeutics Reports Results of Three Phase 2 Clinical Trials of SYI-2074 in Diabetic Patients with Cardiovascular Disease
3. Phase 1/2 Trial of Motexafin Gadolinium Plus Antibody Targeted Radiation Therapy Demonstrates High Complete Response Rate in Patients With Non-Hodgkins Lymphoma
4. Nuvelo Initiates Phase 1B Clinical Trial of Anticoagulant NU172
5. Semafore Pharmaceuticals Reports Positive Interim Results from a Phase I Study of SF1126, a Targeted Pan-PI3K Inhibitor, in Patients with Advanced Solid Tumors
6. Celator(R) Pharmaceuticals Announces Positive Phase 2 Results for CPX-1 in Treatment of Colorectal Cancer
7. Keryx Biopharmaceuticals, Inc. Announces Phase 2 Results on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Waldenstroms Macroglobulinemia at the 44th Annual Meeting of the American Society of Clinical Oncology
8. Delcath Expands Phase III Trial for Metastatic Melanoma to Include St. Lukes Cancer Center
9. Kosans Lead Hsp90 Inhibitor, Tanespimycin, Shows High Level of Activity in Trastuzumab Resistant/Refractory HER2-Positive Breast Cancer in a Phase 2 Trial
10. Amicus Therapeutics Begins Phase 2 Clinical Trial of AT2220 in Pompe Disease
11. EntreMed Presents MKC-1 Phase 2 Data at American Society of Clinical Oncology Annual Meeting

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/1/2009)...NTREAL and DUSSELDORF, Germany, Dec. 1 /PRNewswire...r of specialized graphics solutions, is pleased to...g the Matrox Xenia(TM) Series display controller ... solutions using Fujifilm Synapse. ,, Fujifilm... radiography, offering the world,s first internet-...
(Date:12/1/2009)...H, Calif., Dec. 1 Reproductive Par... Single Embryo Transfer (eSET) Encouragement Progr...ith good embryo quality and a good prognosis for s... transferring a single embryo. ,, The biggest i...reducing the number of multiple pregnancies, even ...
(Date:12/1/2009)... N.J., Dec. 1 Johnson & Johnso.... announced today that it has submitted a New Drug...istration (FDA) for tapentadol extended release (E...the management of moderate to severe chronic pain ...ic pain, defined as pain that persists for long pe...
Breaking Medicine Technology:FUJIFILM Europe Teams Synapse with Matrox Xenia 2FUJIFILM Europe Teams Synapse with Matrox Xenia 3Reproductive Partners Announces Elective Single Embryo Transfer (eSET) Encouragement Program 2New Drug Application Submitted to FDA for Tapentadol Extended Release Tablets for Management of Chronic Pain 2New Drug Application Submitted to FDA for Tapentadol Extended Release Tablets for Management of Chronic Pain 3New Drug Application Submitted to FDA for Tapentadol Extended Release Tablets for Management of Chronic Pain 4New Drug Application Submitted to FDA for Tapentadol Extended Release Tablets for Management of Chronic Pain 5New Drug Application Submitted to FDA for Tapentadol Extended Release Tablets for Management of Chronic Pain 6New Drug Application Submitted to FDA for Tapentadol Extended Release Tablets for Management of Chronic Pain 7US Oncology Inc to Exhibit iKnowMed 28TM 29 at the 2009 ASCO EHR Symposium 3A Harnessing the EHR 3A From Incentives to Sustainability 5225 1US Oncology Inc to Exhibit iKnowMed 28TM 29 at the 2009 ASCO EHR Symposium 3A Harnessing the EHR 3A From Incentives to Sustainability 5225 2US Oncology Inc to Exhibit iKnowMed 28TM 29 at the 2009 ASCO EHR Symposium 3A Harnessing the EHR 3A From Incentives to Sustainability 5225 3Blue Shield of California Awards 2429 6 Million in Pay for Performance Programs in 2009 5223 1Blue Shield of California Awards 2429 6 Million in Pay for Performance Programs in 2009 5223 2SRI International Awarded National Institute of Mental Health Contract for Evaluation of Brain Imaging Agents and Medications for Treatment of Mental 5221 1SRI International Awarded National Institute of Mental Health Contract for Evaluation of Brain Imaging Agents and Medications for Treatment of Mental 5221 2SRI International Awarded National Institute of Mental Health Contract for Evaluation of Brain Imaging Agents and Medications for Treatment of Mental 5221 3
...k to report primary study results in third quarter..., Inc. (Nasdaq: NVAX ) announced today that enro...linical trial of its trivalent virus-like particle... randomized, placebo-controlled study is evaluatin...uenza strains that circulated in the 2008-2009 inf...
... (Nasdaq and MTA: CTIC) announced that data from C...xantrone in patients with advanced, relapsed aggre...ed at the 2009 American Society of Clinical Oncolo...May 29 to June 2, 2009 in Orlando, Florida. , , R...versity of London, an investigator on the study, i...
Other Medicine Technology:Novavax Completes Enrollment of Its Second Phase II Seasonal Influenza VLP Vaccine Clinical Trial 2Novavax Completes Enrollment of Its Second Phase II Seasonal Influenza VLP Vaccine Clinical Trial 3Pixantrone Phase 3 Data to be Presented at the 2009 American Society of Clinical Oncology (ASCO) Annual Meeting 2Pixantrone Phase 3 Data to be Presented at the 2009 American Society of Clinical Oncology (ASCO) Annual Meeting 3
(Date:12/2/2009)... , Ruling by federal government ends nine mont...ELES, Dec. 2 More than ... Permanente facilities across Southern California ...ional Union of Healthcare Workers (NUHW). ,, A ...HW in February, but SEIU delayed the election by f...
(Date:12/2/2009)...Calif.Researchers from the California Institute of...tail, and for the first time, the previously myste...lled ubiquitin are added by enzymes called ubiquit.... Ubiquitin chains tag target proteins for destruc..., "We found that ubiquitin ligases build ubiquiti...
(Date:12/2/2009)...cer patients who have a prostate-specific antigen ...ars after external beam radiation therapy (EBRT) a...cer-related death, according to a study in the Dec...ation Oncology*Biology*Physics, the official journ...(ASTRO)., PSA levels in a prostate cancer patien...
(Date:12/2/2009)...VA Constraint-induced movement therapy (CIMT) is ...hildren with hemiplegic cerebral palsy, but more r...eview published in the November issue of Physical...rican Physical Therapy Association (APTA). The rev...systematic reviews, concluded that further researc...
(Date:12/2/2009)... AB First Aid has been a top name in th...1980. With quality products, professional staff, a...supplies, AB First Aid has established itself as a...ce care, and as a first aid supplies distributor. ...is about to enter into its next phase with the red...
Breaking Medicine News(10 mins):Health News:Labor Board OKs 2,300 Kaiser Professionals to Quit SEIU and Join National Union of Healthcare Workers 2Health News:Caltech scientists show how ubiquitin chains are added to cell-cycle proteins 2Health News:Caltech scientists show how ubiquitin chains are added to cell-cycle proteins 3Health News:Caltech scientists show how ubiquitin chains are added to cell-cycle proteins 4Health News:PSA value at 2 years post-treatment can predict long-term survival in prostate cancer patients 2Health News:Report shows CIMT may improve arm use in children with hemiplegic cerebral palsy 2Health News:From A to B and Everything In-between; AB First Aid Launch New Web Storefront 2Health News:From A to B and Everything In-between; AB First Aid Launch New Web Storefront 3
...is suggested that the fat cells around coronary ar...searchers from the University of Iowa have found... inflammation. Which under certain circumstances, ...art disease, presented their findings to the Exper...
...ays that children's habits are largely determined ...ning if a child would be an avid reader. // “Ch...lded,” said Phillip Dale, professor and chair of t...mponent.” The study used data from more than 6,000...
...ld be trained in the diagnosis and primary treatme...ect, to be conducted by the IMA’s medical specialt...ancial assistance to the project. A memorandum...t has been observed that doctors often shy away fr...
...et helps you to have fewer wrinkles thereby making... People with a normal diet can make their skin ... paprika in their meals, German magazine The Derma...xidants contained in the body stop free-radical da...
...se of light and vitamin B2, promises to be an eye .... // It is well known that almost 10,000 Australia...ed keratoconus, which can ultimately lead to blind...VA light to fall on the eye, which will strengthen...
...and drug resistant and added to this seem to bespr... deadly health menace, according to a warning issu...present in large hospitals for a good many years, ...ny contact with hospitals. Lead researcher a...
Other Medicine News:Health News:Fat Cells Can Trigger Heart Diseases 2Health News:IMA To Train Doctors In Primary Treatment Of HIV/AIDS 2Health News:Golden Staph- the super bug spreads, posing a major health risk. 2
STAARVISC II
...igned with optimum molecular weight and viscosity,...ts and protects the delicate structures of the eye..., adhesion, and pseudoplasticity to satisfy all th...ts from an ophthalmic viscoelastic device. , ,...
...m Hyaluronate (1.8%) viscoelastic solution combine...use. Rayflo maintains a deep anterior chamber and ...y. It is ideal for routine cataract surgery but ca...a viscoelastic. Combine all these properties with ...
...terile, non-pyrogenic, transparent viscoelastic pr...igh molecular weight (average molecular weight 4 m... mg/mL of sodium hyaluronate 5000, dissolved in re...and sodium glucuronate linked by glycosidic bonds....
Medicine Products: